Literature DB >> 20485184

Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology.

Faith Rohlke1, Christina M Surawicz, Neil Stollman.   

Abstract

GOALS: Recurrent Clostridium difficile infection (RCDI) is an increasingly common clinical problem without ideal treatment options. Our aim was to evaluate our results using Fecal Flora Reconstitution (FFR), and promulgate our methodology to the GI community to foster its more widespread use in appropriate candidates.
BACKGROUND: FFR, sometimes termed "fecal transplantion" has been shown in numerous reports to be an effective treatment of RCDI, however, most of these studies have small sample sizes and few focus specifically on the methodology used in colonoscopic preparation and delivery of donated stool. STUDY: Nineteen patients with confirmed multiply recurrent CDI were treated by infusing donor stool through a colonoscope.
RESULTS: Out of 19 patients, 18 initially responded to treatment with a single FFR treatment, 1 patient responded after a second FFR infusion. All 19 patients maintained prolonged cured status followed until submission, ranging from 6 months to 5 years. Three patients were presumed reinfected after remaining symptom free for a period spanning from 6 months to 4 years. These patients tested positive for C. difficile after prescription of additional antibiotics for unrelated infections.
CONCLUSIONS: Fecal Flora Reconstitution is an effective, viable, and simple method of treatment for the difficult to treat patients with RCDI who fail standard therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20485184     DOI: 10.1097/MCG.0b013e3181dadb10

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  48 in total

Review 1.  The human microbiome and its potential importance to pediatrics.

Authors:  Coreen L Johnson; James Versalovic
Journal:  Pediatrics       Date:  2012-04-02       Impact factor: 7.124

2.  Fecal transplantation for the treatment of Clostridium difficile infection.

Authors:  Lawrence J Brandt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

Review 3.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

4.  Fecal matters.

Authors:  Roxanne Palmer
Journal:  Nat Med       Date:  2011-02       Impact factor: 53.440

5.  Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

Review 6.  Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis.

Authors:  R Postigo; J H Kim
Journal:  Infection       Date:  2012-07-31       Impact factor: 3.553

Review 7.  A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics.

Authors:  Emma Allen-Vercoe; Gregor Reid; Norman Viner; Gregory B Gloor; Susy Hota; Peter Kim; Christine Lee; Kieran O'Doherty; Stephen J Vanner; J Scott Weese; Elaine O Petrof
Journal:  Can J Gastroenterol       Date:  2012-07       Impact factor: 3.522

8.  Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease.

Authors:  Olga C Aroniadis; Lawrence J Brandt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-04

Review 9.  Restoring the gut microbiome for the treatment of inflammatory bowel diseases.

Authors:  Jessica R Allegretti; Matthew J Hamilton
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

10.  Fecal microbiota transplantation in relapsing Clostridium difficile infection.

Authors:  Faith Rohlke; Neil Stollman
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.